Scientists Found a New Immune Cell Type That Protects the Gut From Colitis

In a study published in Nature on June 8, 2026, roughly two months ago, researchers identified an entirely new type of protective immune cell living in the gut lining, and showed that a single broken homing gene can explain a rare, severe form of childhood inflammatory bowel disease (IBD). The finding matters beyond that rare condition: the same cell shortage also shows up, to a lesser degree, in common sporadic IBD, giving researchers a fresh, specific target to explain why gut inflammation spirals out of control in some people and not others.

GPR15-Guided CD8+ TIGR Cells Emerge as Gut Protectors

Researchers led by Jing Cui and senior author Michael J. Lenardo at the National Institutes of Health identified a new subset of immune cells they named CD8+ TIGR cells (intramucosal GPR15-guided regulatory CD8+ T lymphocytes), a "regulatory," or calming, type of the CD8+ T cell more commonly known for killing infected or cancerous cells. The cells are guided into the gut lining by a receptor called GPR15 (a protein on the cell surface previously known mainly as an entry point exploited by HIV and related viruses), and when that homing signal is broken by genetic mutation, the protective cells never reach the colon.

Why This Matters for IBD and Colitis Research

Inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease, is a chronic, often lifelong condition, and researchers studying it have long known that CD8+ T cells can be either destructive or protective without a clear way to tell which subset is which; this study gives them a specific marker. The team sequenced the genomes of 7 people from 4 unrelated families with severe early-onset IBD (symptoms including episodic diarrhea, weight loss and failure to thrive) and found rare, damaging GPR15 gene variants shared within each family, present in a gene-dosage pattern where 3 of 4 people carrying two damaged copies were symptomatic versus 4 of 10 carrying just one. Beyond that rare familial disease, the researchers also found CD8+ TIGR cells reduced in the gut lining of people with ordinary, non-genetic ("sporadic") IBD, and in an independent dataset of ulcerative colitis biopsies, these cells were reduced by 42% among all CD8+ T cells, with a similar reduction seen in Crohn's disease tissue, meaning the same cell shortage implicated in the rare monogenic disease also shows up in the far more common form of IBD that most patients have.

How the Researchers Built the Case, From Genes to Mice

The study layered human genetics, population data and mouse experiments to move from a rare familial pattern to a broader, testable mechanism. After identifying the GPR15 variants in the 4 affected families, the researchers tested three much larger, independent populations to see if damaging GPR15 variants were linked to IBD more generally: a Turkish and Qatari cohort of 647 people (74 with IBD), an Iranian cohort of 1,692 people (109 with IBD), and the UK Biobank and All of Us databases, the latter covering more than 250,000 people, in which GPR15 variants were significantly associated with ulcerative colitis. To confirm the mechanism was causal and not just correlated, the team turned to mice genetically engineered to lack GPR15, showing these mice had a selective loss of the same CD8+ cell type from their colon (but not other organs), developed worse colitis, and that this held only when the gene was deleted specifically in CD8+ T cells rather than in the classic FOXP3+ regulatory T cells long assumed to be the important gut-homing cell (a finding that runs counter to prior mouse literature, which had pointed to those FOXP3+ cells instead). Blocking or depleting the inflammatory macrophages that piled up in GPR15-deficient mice, using a drug called clodronate, reduced the colitis, confirming those macrophages as the actual driver of tissue damage once the protective T cells are missing.

What the Findings Mean for People Managing IBD

For someone with IBD, or a family affected by a severe, hard-to-diagnose early-onset bowel disease, the immediate, practical takeaway is limited: this study does not describe a new drug, test or treatment available today. What it does provide is a concrete new biological target: the paper's own discussion section points to therapies designed to restore GPR15 signaling or boost migration of CD8+ TIGR cells into the gut as a plausible, more targeted alternative to today's broad, non-specific anti-inflammatory IBD drugs, though that remains a research direction rather than a treatment. For families with a severe, unexplained pediatric bowel disease, the identification of specific GPR15 variants also raises the possibility that genetic testing could eventually help explain otherwise mysterious early-onset cases, though this study characterized only 4 families and any diagnostic use would need separate validation. Nothing here should be read as changing current IBD treatment or as validating any supplement, diet or existing therapy; this is a mechanism discovery, not a clinical trial.

What's Not Yet Established

The human tissue comparisons at the heart of this mechanism, showing CD8+ T cells and CD8+ TIGR cells depleted in patient gut biopsies, relied on very small groups: 3 patients with the rare GPR15-deficient disease compared against 10 healthy controls and 10 people with ordinary sporadic IBD per group. That is a function of how rare the biallelic GPR15 disease is, not a design flaw, but it means the core human-tissue evidence rests on a handful of people, with the broader case for relevance to common IBD leaning more heavily on the population-genetics cohorts (which covered up to a quarter-million people) and the independent sporadic-IBD replication datasets. It's also worth noting that the version of the paper reviewed for this article was missing its funding and competing-interests statement due to a retrieval issue, though nothing in the study's methods, results or the authors' academic and NIH affiliations suggested any conflict of interest.

What Comes Next

The authors frame their genetic and mouse causal work as a foundation for testing whether restoring GPR15 signaling, or otherwise driving more CD8+ TIGR cells into the gut lining, could become a targeted IBD therapy strategy, though the paper does not lay out a timeline or describe any drug candidate already in testing. IBD is not a rare concern in the U.S.: the CDC's most recent survey data put diagnosed IBD at 1.6% of adults as of 2023 to 2024, which is the scale of chronic disease this kind of mechanistic discovery is ultimately aimed at.

Common Questions

What is a CD8+ TIGR cell? It's a newly identified, regulatory (calming) subset of CD8+ T cells that the study's authors found patrols the gut lining and kills off inflammatory macrophages there; it is guided into place by a receptor called GPR15.

Does this discovery apply to common IBD, or only the rare genetic disease? Both: the GPR15 gene variants explain a rare, severe childhood form of IBD, but the researchers also found the same protective cells reduced in ordinary sporadic ulcerative colitis and Crohn's disease biopsies, just to a smaller degree.

Is there a treatment based on this research available now? No. The paper identifies a mechanism and a potential drug target, restoring GPR15 signaling or CD8+ TIGR cell migration, but does not describe or test any approved or investigational treatment in humans.

How did researchers prove GPR15 loss actually causes worse colitis, rather than just being associated with it? They used mice genetically engineered to lack GPR15 specifically in CD8+ T cells, which developed worse colitis than normal mice, and showed that depleting the resulting excess inflammatory macrophages with a drug reduced that colitis, establishing a causal chain rather than just a correlation.

Key Takeaways

• A Nature study published June 8, 2026 identified a new immune cell type, CD8+ TIGR cells, that is guided into the gut lining by the receptor GPR15 and kills off inflammatory macrophages there.
• Damaging GPR15 gene variants explain a rare, severe early-onset form of IBD in the families studied, and the same protective cells are also reduced (to a lesser degree) in common sporadic ulcerative colitis and Crohn's disease.
• The mechanism was confirmed causally in mice (genetic knockouts plus macrophage-depleting drugs), not just observed as a correlation in human tissue.
• This is a mechanism discovery, not a treatment: the core human biopsy findings rest on a small number of patients (3 patients versus 10 controls per comparison group), and any therapy based on restoring GPR15 signaling remains an unstudied future direction.

References

Tingyue Zhou, Shu Zhu (2026). Beyond FOXP3: gut tolerogenic CD8 ⁺ T cells. Vita. https://doi.org/10.15302/vita.2026.07.0058